- BMO Capital Markets initiated coverage on 4D Molecular Therapeutics Inc (NASDAQ:FDMT) with an Outperform rating and a price target of $50.
- The analyst writes that 4DMT’s platform has generated competitive gene therapies and been clinically validated through its five ongoing clinical programs.
- BMO notes that 4D Molecular Therapeutics’ Wet Age-Related Macular Degeneration (wet AMD) program addresses key limitations of approved/investigational therapies and can potentially confer a $5 billion opportunity.
- Also Read: HC Wainwright Creates Bullish Pitch On 4D Molecular Citing ‘Broader Systemic Potential.’
- The company’s cystic Fibrosis asset 4D-710 can be the first therapy delivering clinical effects in patients without treatment options, potentially unlocking around $3 billion opportunity.
- In cystic fibrosis, a 3-5%+ improvement in FEV1 can drive FDMT stock over 50% higher and render the stock an attractive acquisition target.
- Potential announcements around partnerships would trigger further upside.
- Price Action: FDMT shares are up 0.96% at $21.47 on the last check Monday.
NIO, Lucid Group And Other Big Gainers From Monday
U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session.
